Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000593959 | SCV000702435 | uncertain significance | not provided | 2016-10-21 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002413672 | SCV002715380 | uncertain significance | Cardiovascular phenotype | 2019-11-21 | criteria provided, single submitter | clinical testing | The p.A5640T variant (also known as c.16918G>A), located in coding exon 65 of the TTN gene, results from a G to A substitution at nucleotide position 16918. The alanine at codon 5640 is replaced by threonine, an amino acid with similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV002497251 | SCV002816070 | uncertain significance | Dilated cardiomyopathy 1G; Autosomal recessive limb-girdle muscular dystrophy type 2J; Tibial muscular dystrophy; Myopathy, myofibrillar, 9, with early respiratory failure; Early-onset myopathy with fatal cardiomyopathy; Hypertrophic cardiomyopathy 9 | 2021-09-01 | criteria provided, single submitter | clinical testing |